Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma

Table 1 Baseline patient data

Variables	T + A (n = 58)	T + L (n = 42)	T + S (n = 64)	T + D (n = 49)	P value
Age (≥ 55/< 55)	33/25	33/9	36/28	30/19	0.092
Sex (female/male)	10/48	6/36	7/57	8/41	0.768
Etiology					0.075
Hepatitis B virus	54	40	60	47
Hepatitis C virus	0	0	0	0
Others	4	2	4	2
AFP level (ng/mL)					0.084
≤ 400	26	14	18	24
> 400	32	28	46	25
ALT (U/L)					0.483
≤ 40	12	8	19	14
> 40	46	34	45	35
AST (U/L)					0.087
≤ 40	5	2	12	9
> 40	53	40	52	40
VEGF (pg/mL), mean (SD)	456.06 (216.38)	412.81 (163.02)	403.03 (168.45)	417.99 (170.99)	0.419
Cirrhosis
No	0	0	0	0
Yes	58	42	64	49
Child-Pugh class					0.102
A	41	24	49	29
B	17	18	15	20
Tumor size (cm)					0.103
≤ 5	34	18	41	23
> 5	24	24	23	26
Tumor number					0.338
Single	21	12	15	11
Multiple	37	30	49	38
Metastasis					0.091
Yes	18	20	16	19
No	40	22	48	30
BCLC stage					0.471
B	38	22	35	26
C	20	20	29	23

AFP: Alpha fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; T + A: Transcatheter arterial chemoembolization combined with apatinib group; T + L: Transcatheter arterial chemoembolization combined with lenvatinib group; T + S: Transcatheter arterial chemoembolization combined with sorafenib group; T + D: Transcatheter arterial chemoembolization combined with donafenib group; VEGF: Vascular endothelial growth factor; BCLC: Barcelona Clinic Liver Cancer.